A Perdriger (Professeur) , A Courtillon (Directeur médical)
{"title":"类风湿性关节炎新闻","authors":"A Perdriger (Professeur) , A Courtillon (Directeur médical)","doi":"10.1016/j.emck.2003.08.001","DOIUrl":null,"url":null,"abstract":"<div><p>The medical management of rheumatoid arthritis has moved in recent years towards early initiation of individually tailored second therapy aimed at slowing the pace of joint destruction. The treatment armamentarium has expanded with addition of chemical agents such as leflunomide and of biotherapies such as molecules directed against tumour necrosis factor or interleukine 1. The board array of medical treatments available today requires the development of treatment strategies that should include drug combinations for those patients at the most severe end of disease severity spectrum. Control of the joint inflammation is a prerequisite to effective rehabilitation therapy.</p></div>","PeriodicalId":100445,"journal":{"name":"EMC - Podologie-Kinésithérapie","volume":"1 1","pages":"Pages 38-42"},"PeriodicalIF":0.0000,"publicationDate":"2004-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.emck.2003.08.001","citationCount":"0","resultStr":"{\"title\":\"Actualités sur la polyarthrite rhumatoïde\",\"authors\":\"A Perdriger (Professeur) , A Courtillon (Directeur médical)\",\"doi\":\"10.1016/j.emck.2003.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The medical management of rheumatoid arthritis has moved in recent years towards early initiation of individually tailored second therapy aimed at slowing the pace of joint destruction. The treatment armamentarium has expanded with addition of chemical agents such as leflunomide and of biotherapies such as molecules directed against tumour necrosis factor or interleukine 1. The board array of medical treatments available today requires the development of treatment strategies that should include drug combinations for those patients at the most severe end of disease severity spectrum. Control of the joint inflammation is a prerequisite to effective rehabilitation therapy.</p></div>\",\"PeriodicalId\":100445,\"journal\":{\"name\":\"EMC - Podologie-Kinésithérapie\",\"volume\":\"1 1\",\"pages\":\"Pages 38-42\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.emck.2003.08.001\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMC - Podologie-Kinésithérapie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1762567X03000028\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMC - Podologie-Kinésithérapie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1762567X03000028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The medical management of rheumatoid arthritis has moved in recent years towards early initiation of individually tailored second therapy aimed at slowing the pace of joint destruction. The treatment armamentarium has expanded with addition of chemical agents such as leflunomide and of biotherapies such as molecules directed against tumour necrosis factor or interleukine 1. The board array of medical treatments available today requires the development of treatment strategies that should include drug combinations for those patients at the most severe end of disease severity spectrum. Control of the joint inflammation is a prerequisite to effective rehabilitation therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
